Detailed Analysis

Agency and Opportunity Overview

• Agency: Food and Drug Administration (FDA)
• Opportunity Type: Request for Information (RFI)
• RFI Number: (Not specified in the provided text, vendor should include in response)
• Project Name/Number: OII-Extended Reality/Reality Simulation Training & Development Capability
• NAICS Code: (Not specified in the provided text, but vendor should include in response)

Objectives and Requirements

The FDA, specifically the Office of Inspections and Investigations (OII), seeks to modernize its training programs by integrating AI-powered Extended Reality (XR) solutions. The primary objectives are:

• To broaden FDA’s understanding of current market capability on Artificial Intelligence-powered Extended Reality (XR) reality simulation tools such as Augmented Reality (AR) or Virtual Application (VR) training platforms to provide the next generation immersive learning, experiential learning, and microlearning opportunities for FDA regulatory inspection/investigation workforce.

• Provide digital engineering, modelling and simulation via augmented reality and virtual reality service to FDA inspection personnel.
• Enhance training effectiveness through adaptive gamified learning environments.
• Develop customizable learning interfaces for personalized and adaptable training.
• Foster a team learning environment through multi-user capabilities.
• Develop complete, pre-packaged, and validated scenario-based AR/VR training systems.
• Ensure training solutions integrate with the agency's Learning Management Systems (LMS).
• Include built-in features for real-time feedback on learning progress.

The FDA envisions a future state with:

• Immersive training programs with realistic and interactive modules.
• Simulation for skill development with instant feedback and analytics.
• Enhanced trainee engagement through collaboration in virtual spaces.
• Integration of digital information with current training.
• Microlearning and experiential learning capabilities.
• Scalable infrastructure to support multiple geographically dispersed users.

A high-level use case is provided for sample collection, including specific steps for collecting aseptic samples of blueberries and grits at an imports warehouse and preparing them for shipping.

Submission Guidelines and Timeline

• Submission Deadline: January 2, 2025
• Submission Method: Email to Vivianna Diaz, [email protected]
• Subject Line: Include the RFI number
• Content: Capability Statement limited to 10 pages
• Restrictions: >Do not send information that requires a non-disclosure agreement or sensitive business information. Telephone inquiries will not be accepted or acknowledged, and no feedback or evaluations will be provided to companies regarding their submissions.

Interested parties must respond to the 24 questions provided in the RFI document and include business information such as:

• Company Name
• Company Address
• Company Point of Contact, phone number, and email address.
• Type of company under NAICS, as validated via the System for Award Management (SAM).
• Small Business Socioeconomic program, if applicable
• Corporate structure
• Current GSA Schedules appropriate to this Sources Sought
• Point of Contact, phone number and email address of individuals who can verify the demonstrated capabilities identified in the response.
• Please provide publicly posted pricing such as price catalogs in accordance with FAR Part 10 or a copy of your commercial price catalog as market research as well as software solutions pricing methodology.

Evaluation and Acquisition Strategy

• Contract Type: Not applicable, this is an RFI for market research purposes only.
• Set-Aside: Not applicable.
• Evaluation Criteria: Responses will be reviewed by FDA personnel and held in a confidential manner. The RFI states that >Information obtained because of this notice may be used by the FDA for program planning on a non‐attribution basis.